Bangkok, Thailand — 2025
In a groundbreaking step to accelerate regenerative medicine and advanced biologics, Villa Medical Center Phuket (www.thailandstemcell.com) is proud to announce a strategic partnership with Mahidol University, one of Thailand’s leading biomedical institutions, to establish a dedicated exosome isolation and characterization facility in 2025. This initiative aims to bolster Thailand’s position in cutting-edge stem cell therapy, exosome-based treatment, and Advanced Therapy Medicinal Product (ATMP) development.
As a regional subsidiary of Atlantis Bioscience Singapore (www.atlantisbioscience.com), Villa Medical Center Phuket continues to expand its influence in Asia’s biomedical ecosystem. The collaboration with Mahidol—ranked among Asia’s top universities in life sciences—marks a new era of translational research and GMP-compatible exosome technology that serves clinical, academic, and commercial needs.
Why Exosomes Are the Next Frontier in Regenerative and Immune Therapy
Exosomes, also known as extracellular vehicles (EVs), are nanoscale particles secreted by cells that play vital roles in cell-to-cell communication, tissue repair, inflammation control, and immune modulation. Derived commonly from mesenchymal stem cells (MSCs), exosomes are increasingly used in experimental and commercial therapies due to their ability to carry signalling molecules such as microRNAs, proteins, lipids, and growth factors.
Their therapeutic potential spans across:
- Neurological conditions like Parkinson’s and Alzheimer’s
- Orthopaedic regeneration and wound healing
- Autoimmune modulation in diseases like lupus or MS
- Aesthetic and dermatological rejuvenation
- Oncology as drug delivery vehicles or immune modulators
Unlike full cell therapies, exosome therapy is cell-free, reducing the risk of immune rejection, tumorigenicity, and storage limitations. Exosomes are considered a new class of ATMPs with global interest and investment.
Exosome Isolation at Mahidol: A National Resource Center
With this initiative, Villa Medical Center Phuket and Mahidol University aim to establish the first standardized exosome isolation facility in Thailand, capable of supporting:
- Research-grade and preclinical production
- GMP-ready protocols for future clinical trials
- Comprehensive QC including NTA, Western blot, and TEM analysis
- Storage and stability studies under Thai FDA guidance
The facility will be located within Mahidol’s Faculty of Medicine and Department of Biochemistry, leveraging its advanced instrumentation, cross-departmental expertise, and internationally accredited labs.
Capabilities and Workflow Highlights
The exosome isolation platform will employ cutting-edge methods including:
- Ultracentrifugation and tangential flow filtration (TFF)
- Polymer-based precipitation for scalability
- Size exclusion chromatography (SEC) for purity
- Microfluidics-based on-chip sorting
- GMP-compatible buffer systems from Atlantis Bioscience
Post-isolation, the exosomes will undergo:
- Nanoparticle tracking analysis (NTA) for size and concentration
- Transmission electron microscopy (TEM) for structural confirmation
- Flow cytometry for CD63, CD9, CD81 surface markers
- Western blotting for exosome protein profiling
This high-resolution isolation and validation system ensures that exosomes meet the strict criteria for research and eventual clinical application.
The Role of Atlantis Bioscience Singapore: Innovation Meets Infrastructure
Atlantis Bioscience Singapore will provide the foundational technologies and SOPs for the isolation lab, including:
- GMP reagents for EV-friendly culture media
- Serum-free exosome production kits
- Isolation buffers with proven batch-to-batch consistency
- Cryopreservation systems for long-term stability
- Staff training in ISO and GMP standards
This ensures that the Mahidol facility aligns with global benchmarks in exosome therapeutics and cell-free ATMP development.
Atlantis Bioscience also brings its experience from collaborations across China, Malaysia, and Indonesia in building cell therapy-ready infrastructure tailored to ASEAN compliance frameworks and international harmonization standards.
Applications in MSC and Stem Cell Therapy
Exosome therapy is emerging as a powerful extension of stem cell therapy, particularly for patients who may not qualify for full cell-based treatments due to safety or regulatory concerns.
With MSC-derived exosomes, many of the anti-inflammatory, angiogenic, and immunomodulatory properties of stem cells can be delivered in a cell-free format. These benefits make exosomes ideal for:
- Injectable formulations for joint pain and osteoarthritis
- Topical delivery in cosmetic and wound applications
- Intravenous use in systemic inflammatory conditions
The facility at Mahidol will specialize in exosome isolation from:
- Umbilical cord MSCs
- Adipose-derived stem cells (ADSCs)
- Bone marrow stem cells (BMSCs)
- Cancer cell lines for experimental immunology
Academic Collaboration and Training Programs
The partnership includes an academic component to nurture Thailand’s next generation of exosome researchers. Planned initiatives include:
- A Certificate Program in Exosome Science and Technology
- Workshops in exosome isolation, characterization, and data analysis
- Joint publications in high-impact regenerative medicine journals
- Thesis support for Mahidol graduate and PhD students
These efforts align with Thailand’s national bioeconomy strategy, which seeks to build scientific capacity and commercialize academic research.
Toward GMP and Clinical-Grade Exosome Therapy
While the initial focus is on research and preclinical exosome applications, Villa Medical Center Phuket plans to use this facility as the foundation for Thailand’s first GMP exosome manufacturing line by 2026.
This would enable:
- Thai clinical trials in dermatology, orthopedics, and neurodegeneration
- Partnerships with cosmetic brands for exosome-infused skin care products
- Licensing of Thai exosome products to other ASEAN markets
GMP compliance, as supported by Atlantis Bioscience, will allow the facility to pursue Thai FDA certification and become a launchpad for exportable Thai exosome therapies.
A New Era for Thai Biotech Innovation
This partnership reflects a broader shift toward advanced biologics in Thai medicine. The Mahidol exosome facility stands to benefit:
- Hospitals seeking clinical-grade EVs for pilot programs
- Cosmetic clinics integrating regenerative formulations
- Startups creating exosome-based delivery systems
- Academic labs moving from research to product development
With access to world-class protocols and ongoing support from Atlantis Bioscience, the facility will place Thailand on the global map for exosome research and production.
Conclusion: Building Thailand’s Exosome Future with Atlantis and Mahidol
With the 2025 launch of an exosome isolation facility at Mahidol University, Villa Medical Center Phuket is once again setting the benchmark for scientific leadership in Thailand’s regenerative medicine ecosystem. Backed by the technology and expertise of Atlantis Bioscience Singapore, the collaboration embodies a scalable, scientifically sound, and ethically guided approach to next-generation stem cell therapy and cell-free ATMPs.
As the world looks toward exosomes for solutions in aging, chronic disease, and personalized therapy, Thailand now stands equipped with the infrastructure, talent, and vision to lead.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969